Lista de obras -

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

artículo científico publicado en 2016

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population

artículo científico publicado en 2017

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

artículo científico publicado en 2011

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

artículo científico publicado en 2011

AT-19SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.

artículo científico publicado en 2014

AT-20SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).

artículo científico publicado en 2014

AT-21FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).

artículo científico publicado en 2014

ATCT-01PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG).

artículo científico publicado en 2015

ATCT-13BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION: A PHASE II TRIAL.

artículo científico publicado en 2015

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

artículo científico publicado en 2010

Adjunctive perampanel for glioma-associated epilepsy

An evidence-based comparison of operational criteria for the presence of sarcopenia

artículo científico publicado en 2014

Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures

artículo científico publicado en 2012

Association of change in muscle mass assessed by D3 -creatine dilution with changes in grip strength and walking speed

scientific article published on 17 October 2019

Bevacizumab and daily temozolomide for recurrent glioblastoma

artículo científico publicado en 2011

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

artículo científico publicado en 2012

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma

artículo científico publicado en 2011

Circulating vitamin D, supplement use, and cardiovascular disease risk: the MrOS Sleep Study

artículo científico publicado en 2014

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial

artículo científico publicado en 2013

Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project

artículo científico publicado en 2014

Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness

artículo científico publicado en 2014

Cystatin C and cognitive impairment 10 years later in older women

artículo científico publicado en 2014

Depressive symptoms and circadian activity rhythm disturbances in community-dwelling older women

artículo científico publicado en 2013

Depressive symptoms and subjective and objective sleep in community-dwelling older women

artículo científico publicado en 2012

Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab ⬇️

artículo científico publicado el 8 de enero de 2011

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

artículo científico publicado en 2010

Everolimus tablets for patients with subependymal giant cell astrocytoma

artículo científico publicado en 2011

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma

artículo científico publicado en 2011

Grip strength cutpoints for the identification of clinically relevant weakness

scientific article published on May 2014

Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States

artículo científico publicado en 2020

IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).

artículo científico publicado en 2015

IT-34PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).

artículo científico publicado en 2014

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma

scientific article published on 06 March 2020

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

artículo científico publicado en 2014

Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in men study

artículo científico publicado en 2014

ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN RECURRENT GLIOBLASTOMA (GBM): FIRST PHASE I CLINICAL TRIAL EVALUATING THE INTRATUMORAL ADMINISTRATION.

artículo científico publicado en 2014

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

artículo científico publicado en 2011

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

artículo científico publicado en 2012

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

artículo científico publicado en 2011

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

artículo científico publicado en 2011

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

artículo científico publicado en 2017

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

artículo científico publicado en 2017

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

artículo científico publicado en 2018

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

artículo científico publicado en 2015

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

artículo científico publicado en 2012

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

artículo científico publicado en 2011

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

artículo científico publicado en 2011

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

artículo científico publicado en 2010

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

artículo científico publicado en 2016

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

artículo científico publicado en 2013

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis

publication published on 21 September 2021

QL-20PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA.

artículo científico publicado en 2014

QL-21SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS.

artículo científico publicado en 2014

QOL-19PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN.

artículo científico publicado en 2015

QOL-20LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY.

artículo científico publicado en 2015

QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION.

artículo científico publicado en 2015

RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events

scientific article published on 27 February 2020

RTRB-04STEREOTACTIC RADIOSURGERY FOR RECURRENT HIGH-GRADE GLIOMAS: PATIENT SELECTION AND THE ROLE OF BEVACIZUMAB.

artículo científico publicado en 2015

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

artículo científico publicado en 2018

Response to BONE-D-14-00884.

artículo científico publicado en 2014

Risk Factors for Hip Fracture in Older Men: The Osteoporotic Fractures in Men Study (MrOS).

artículo científico publicado en 2016

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas

artículo científico publicado en 2011

Screening for Osteoporosis in Older Men: Operating Characteristics of Proposed Strategies for Selecting Men for BMD Testing

artículo científico publicado en 2017

Second primary cancers in long-term survivors of glioblastoma

scientific article published on 04 February 2019

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice

Strong Relation Between Muscle Mass Determined by D3-creatine Dilution, Physical Performance, and Incidence of Falls and Mobility Limitations in a Prospective Cohort of Older Men.

artículo científico publicado en 2019

Subjective and objective sleep disturbance and longitudinal risk of depression in a cohort of older women

artículo científico publicado en 2014

The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates

artículo científico publicado en 2014

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

artículo científico publicado en 2011

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report ⬇️

artículo científico publicado el 8 de abril de 2010

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

artículo científico publicado en 2010

Volumetric Bone Mineral Density and Failure Load of Distal Limbs Predict Incident Clinical Fracture Independent of FRAX and Clinical Risk Factors Among Older Men.

artículo científico publicado en 2018

Lista de obras de

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

AT-19SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.

AT-20SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).

AT-21FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).

ATCT-01PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG).

ATCT-13BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION: A PHASE II TRIAL.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Adjunctive perampanel for glioma-associated epilepsy

An evidence-based comparison of operational criteria for the presence of sarcopenia

Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures

Association of change in muscle mass assessed by D3 -creatine dilution with changes in grip strength and walking speed

Bevacizumab and daily temozolomide for recurrent glioblastoma

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma

Circulating vitamin D, supplement use, and cardiovascular disease risk: the MrOS Sleep Study

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial

Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project

Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness

Cystatin C and cognitive impairment 10 years later in older women

Depressive symptoms and circadian activity rhythm disturbances in community-dwelling older women

Depressive symptoms and subjective and objective sleep in community-dwelling older women

Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab ⬇️

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Everolimus tablets for patients with subependymal giant cell astrocytoma

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma

Grip strength cutpoints for the identification of clinically relevant weakness

Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States

IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).

IT-34PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in men study

ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN RECURRENT GLIOBLASTOMA (GBM): FIRST PHASE I CLINICAL TRIAL EVALUATING THE INTRATUMORAL ADMINISTRATION.

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis

QL-20PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA.

QL-21SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS.

QOL-19PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN.

QOL-20LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY.

QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION.

RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events

RTRB-04STEREOTACTIC RADIOSURGERY FOR RECURRENT HIGH-GRADE GLIOMAS: PATIENT SELECTION AND THE ROLE OF BEVACIZUMAB.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Response to BONE-D-14-00884.

Risk Factors for Hip Fracture in Older Men: The Osteoporotic Fractures in Men Study (MrOS).

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas

Screening for Osteoporosis in Older Men: Operating Characteristics of Proposed Strategies for Selecting Men for BMD Testing

Second primary cancers in long-term survivors of glioblastoma

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice

Strong Relation Between Muscle Mass Determined by D3-creatine Dilution, Physical Performance, and Incidence of Falls and Mobility Limitations in a Prospective Cohort of Older Men.

Subjective and objective sleep disturbance and longitudinal risk of depression in a cohort of older women

The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report ⬇️

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

Volumetric Bone Mineral Density and Failure Load of Distal Limbs Predict Incident Clinical Fracture Independent of FRAX and Clinical Risk Factors Among Older Men.